<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01204684</url>
  </required_header>
  <id_info>
    <org_study_id>10-000202</org_study_id>
    <nct_id>NCT01204684</nct_id>
  </id_info>
  <brief_title>Dendritic Cell Vaccine for Patients With Brain Tumors</brief_title>
  <official_title>A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen +/- Toll-like Receptor Agonists for the Treatment of Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the most effective immunotherapy vaccine&#xD;
      components in patients with malignant glioma. Teh investigators previous phase I study (IRB&#xD;
      #03-04-053) already confirmed that this vaccine procedure is safe in patients with malignant&#xD;
      brain tumors, and with an indication of extended survival in several patients. However, the&#xD;
      previous trial design did not allow us to test which formulation of the vaccine was the most&#xD;
      effective. This phase II study will attempt to dissect out which components are most&#xD;
      effective together. Dendritic cells (DC) (cells which &quot;present&quot; or &quot;show&quot; cell identifiers to&#xD;
      the immune system) isolated from the subject's own blood will be treated with tumor-cell&#xD;
      lysate isolated from tumor tissue taken from the same subject during surgery. This pulsing&#xD;
      (combining) of antigen-presenting and tumor lysate will be done to try to stimulate the&#xD;
      immune system to recognize and destroy the patient's intracranial brain tumor. These pulsed&#xD;
      DCs will then be injected back into the patient intradermally as a vaccine. The investigators&#xD;
      will also utilize adjuvant imiquimod or poly ICLC (interstitial Cajal-like cell) in some&#xD;
      treatment cohorts. It is thought that the host immune system might be taught to &quot;recognize&quot;&#xD;
      the malignant brain tumor cells as &quot;foreign&quot; to the body by effectively presenting unique&#xD;
      tumor antigens to the host immune cells (T-cells) in vivo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 8, 2010</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Most effective combination of DC vaccine components</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression and overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glioma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Anaplastic Astro-oligodendroglioma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Tumor Lysate-pulsed DC vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort #1 will receive autologous tumor lysate-pulsed DC vaccination together with a placebo cream or intramuscular injection of saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor lysate-pulsed DC vaccination+0.2% resiquimod.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort #2 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant 0.2% resiquimod.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor-lysate pulsed DC vaccination +adjuvant polyICLC.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort #3 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant poly ICLC (TLR3 agonist).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous tumor lysate-pulsed DC vaccination</intervention_name>
    <arm_group_label>Tumor Lysate-pulsed DC vaccination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tumor lysate-pulsed DC vaccination+0.2% resiquimod</intervention_name>
    <arm_group_label>Tumor lysate-pulsed DC vaccination+0.2% resiquimod.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tumor-lysate pulsed DC vaccination +adjuvant polyICLC</intervention_name>
    <arm_group_label>Tumor-lysate pulsed DC vaccination +adjuvant polyICLC.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PATIENT ELIGIBILITY&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          1. Patients with newly diagnosed or recurrent glioma of WHO Grade III or IV {anaplastic&#xD;
             astrocytoma (AA), anaplastic astro-oligodendroglioma (AO), or glioblastoma (GBM)} will&#xD;
             be eligible for this protocol.&#xD;
&#xD;
          2. Patients must have had surgical resection at UCLA (University of California, Los&#xD;
             Angeles), for which a separate informed consent was signed for the collection of their&#xD;
             tumor prior to surgery.&#xD;
&#xD;
          3. After surgery, a pathological diagnosis of malignant glioma (WHO Grade III or IV) will&#xD;
             need to be established.&#xD;
&#xD;
          4. Patients must be 18 years or older and able to read and understand the informed&#xD;
             consent document. Patients must sign the informed consent indicating that they are&#xD;
             aware of the investigational nature of this study.&#xD;
&#xD;
          5. Patients must have a Karnofsky performance status (KPS) rating of &gt; 60 prior to&#xD;
             initiating treatment. Patients may be enrolled at a KPS of &lt; 60 if it is felt that the&#xD;
             patient will have adequate opportunity to recover to a KPS of &gt; 60 by the initiation&#xD;
             of treatment.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Subjects with an active infection.&#xD;
&#xD;
          2. Inability to obtain informed consent because of psychiatric or complicating medical&#xD;
             problems.&#xD;
&#xD;
          3. Unstable or severe intercurrent medical or psychiatric conditions as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          4. Females of child-bearing potential who are pregnant or lactating or who are not using&#xD;
             approved contraception.&#xD;
&#xD;
          5. History of immunodeficiency (e.g., HIV) or autoimmune disease (e.g., rheumatoid&#xD;
             arthritis, systemic lupus erythematosus, vasculitis, polymyositis-dermatomyositis,&#xD;
             scleroderma, multiple sclerosis, or juvenile-onset insulin-dependent diabetes) that&#xD;
             may be exacerbated by immunotherapy.&#xD;
&#xD;
          6. Subjects with organ allografts.&#xD;
&#xD;
          7. Inability or unwillingness to return for required visits and follow-up exams.&#xD;
&#xD;
          8. Subjects who have an uncontrolled systemic malignancy that is not in remission.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Los Angeles, California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999 Jun;90(6):1115-24.</citation>
    <PMID>10350260</PMID>
  </reference>
  <reference>
    <citation>Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005 Aug 1;11(15):5515-25.</citation>
    <PMID>16061868</PMID>
  </reference>
  <reference>
    <citation>Prins RM, Liau LM. Cellular immunity and immunotherapy of brain tumors. Front Biosci. 2004 Sep 1;9:3124-36. Review.</citation>
    <PMID>15353342</PMID>
  </reference>
  <reference>
    <citation>Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008 Jul 31;359(5):539-41. doi: 10.1056/NEJMc0804818.</citation>
    <PMID>18669440</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2010</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dendritic cells</keyword>
  <keyword>glioma</keyword>
  <keyword>vaccine</keyword>
  <keyword>glioma of WHO Grade III or IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

